With this rapid growth, Ardelyx increased its 2025 IBSRELA sales projection to $250 million to $260 million, demonstrating management's growing confidence in the product's long-term prospects. XPHOZAH, its second important asset, is used to reduce serum phosphate (phosphorus) levels in individuals with chronic kidney disease (CKD) on dialysis who have hyperphosphatemia, a condition characterized by an excess of phosphate in the blood. XPHOZAH is gaining appeal among nephrologists, boasting net sales of $25 ...